TEVA BIOPHARMACEUTICALS USA IN has a total of 12 patent applications. Its first patent ever was published in 2007. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Republic of Korea. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are APOTECH R & D SA, CUREDM INC and CUREDM GROUP HOLDINGS LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 3 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Republic of Korea | 2 | |
#4 | United States | 2 | |
#5 | Canada | 1 | |
#6 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Roschke Viktor | 6 |
#2 | Kanakaraj Palanisamy | 6 |
#3 | Smith Rodger | 5 |
#4 | Cooksey Bridget A | 3 |
#5 | Rosen Craig | 3 |
#6 | Bock Jason Benjamin | 3 |
#7 | Bell Adam Carr | 2 |
#8 | Herpst Jeffrey | 2 |
#9 | Smith Roger | 1 |
#10 | Luo Xia | 1 |
Publication | Filing date | Title |
---|---|---|
CA2677163A1 | Humanized antibodies against cxcr3 | |
EP2054437A2 | Albumin-insulin fusion proteins |